NYSE:NUVBPharmaceuticals
How Investors May Respond To Nuvation Bio (NUVB) EMA Review Of Taletrectinib Milestone Opportunity
Nuvation Bio recently reported that the European Medicines Agency validated its Marketing Authorization Application for taletrectinib (IBTROZI) to treat advanced ROS1-positive non-small cell lung cancer, starting a formal review process that could eventually unlock US$30,000,000 in milestone payments from partner Eisai if approval in the European Union is granted.
This regulatory progress in Europe adds a fresh potential revenue stream and external validation for Nuvation Bio’s oncology...